Market closedNon-fractional
Cara Therapeutics/CARA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Cara Therapeutics
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
Ticker
CARA
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Stamford, United States
Employees
55
Website
www.caratherapeutics.com
CARA Metrics
BasicAdvanced
$20M
Market cap
-
P/E ratio
-$2.26
EPS
0.73
Beta
-
Dividend rate
Price and volume
Market cap
$20M
Beta
0.73
Financial strength
Current ratio
5.381
Quick ratio
4.816
Long term debt to equity
151.666
Total debt to equity
152.404
Interest coverage (TTM)
-46.83%
Management effectiveness
Return on assets (TTM)
-62.20%
Return on equity (TTM)
-147.29%
Valuation
Price to revenue (TTM)
1.171
Price to book
0.67
Price to tangible book (TTM)
0.67
Price to free cash flow (TTM)
-0.218
Growth
Revenue change (TTM)
-60.83%
Earnings per share change (TTM)
43.90%
3-year revenue growth (CAGR)
-49.16%
3-year earnings per share growth (CAGR)
98.22%
What the Analysts think about CARA
Analyst Ratings
Majority rating from 5 analysts.
CARA Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$2.1M
-30.00%
Net income
-$31M
-5.26%
Profit margin
-1,457.14%
35.34%
CARA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.58
-$0.52
-$0.59
-$0.56
-
Expected
-$0.54
-$0.52
-$0.41
-$0.40
-$0.27
Surprise
7.74%
0.00%
43.20%
40.70%
-
CARA News
AllArticlesVideos
These Cara Therapeutics Analysts Are No Longer Bullish: 'We See No Obvious Future Value Drivers'
Benzinga·1 month ago
Cara Therapeutics discontinues study on a neurological condition as drug fails
Reuters·1 month ago
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cara Therapeutics stock?
Cara Therapeutics (CARA) has a market cap of $20M as of July 26, 2024.
What is the P/E ratio for Cara Therapeutics stock?
The price to earnings (P/E) ratio for Cara Therapeutics (CARA) stock is 0 as of July 26, 2024.
Does Cara Therapeutics stock pay dividends?
No, Cara Therapeutics (CARA) stock does not pay dividends to its shareholders as of July 26, 2024.
When is the next Cara Therapeutics dividend payment date?
Cara Therapeutics (CARA) stock does not pay dividends to its shareholders.
What is the beta indicator for Cara Therapeutics?
Cara Therapeutics (CARA) has a beta rating of 0.73. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Cara Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.